a. Efficacy: Mortality, morbidity (symptom burden, symptom improvement, time to healing), quality of life (patient-based outcomes, such as cosmetic appearance, QoL or depression scores), resource use (e.g. length of hospital stay), return to normal activities, recurrence and tumour response measures<br>b. Safety: Adverse events (ulceration of the underlying tissues, haemoptysis, scarring, carcinogenicity, oesophageal strictures, cardiac complications, nausea, inflammation, pain, constipation) (p. 8)

precancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

various